Application No.: 10/766,106 Docket No.: PRJ-006CNRCE2

AMENDMENTS TO THE CLAIMS

1-11. (Cancelled)

12. **(Original)** A method for producing a pharmaceutical formulation for controlled release of an interferon, the method comprising:

dissolving (a) a biodegradable polymer and (b) a conjugate of an interferon and a hydrophilic polymer in a solvent to form a monophase, and

forming microparticles or nanoparticles comprising the biodegradable polymer encapsulating the conjugate.

- 13. (Original) The method of claim 12, wherein the interferon is selected from the group consisting of alpha-interferon, beta-interferon, and gamma-interferon.
- 14. (Previously presented) A pharmaceutical formulation for controlled release of an interferon, the formulation comprising a biodegradable polymer in combination with a conjugate of an interferon and a hydrophilic polymer, wherein the biodegradable polymer comprises a derivatized biodegradable polymer containing hydrophilic and hydrophobic regions, and wherein the interferon is selected from the group consisting of α -interferon, β -interferon, and γ -interferon.
- 15. (Original) The formulation of claim 14, wherein the hydrophilic region comprises polyethylene glycol.
- 16. **(Original)** The formulation of claim 14, wherein the hydrophobic region comprises a polymer selected from the group consisting of polyhydroxy acids, polylactic acids, polyglycolic acids, and copolymers thereof.

17-18. (Cancelled)

Application No.: 10/766,106 Docket No.: PRJ-006CNRCE2

19. **(Original)** A pharmaceutical formulation for controlled release of a bioactive molecule, the formulation comprising a biodegradable polymer in combination with a conjugate of a bioactive molecule and a hydrophilic polymer, wherein the formulation is in the form of microparticles encapsulating the conjugate, the microparticles having a diameter predominantly between 20 and 100 um.

- 20. (Original) The pharmaceutical formulation of claim 19, wherein the bioactive molecule is a protein.
- 21-23. (Cancelled)
- 24. (Previously presented) The pharmaceutical formulation of claim 19, wherein the bioactive molecule is insulin, α -interferon, β -interferon, or γ -interferon.